New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025Upon FDA approval, ...
Discover key insights from Lenz Therapeutics' Q4 2024 earnings call, showcasing LNZ100's progress towards launch, a $3B market potential, and FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback